Injectable BPC-157 reaches tissue concentrations the oral route cannot match for most non-gut uses
Persistently low or abnormal glutathione markers warrant medical evaluation when they occur with liver disease, chronic kidney disease, malnutrition, malabsorption, uncontrolled diabetes, heavy alcohol exposure, or symptoms of systemic illness
Also, a small non-randomized study 15 in two older adults treated with ALC (2 g/day for 12 weeks), reported a decrease in HDRS scores from 15 to 0 and from 20 to 3 by week 12 and compared outcomes with six non-depressed controls
Injection site reactions: Mild redness or irritation at the subcutaneous injection site
what you eat plays a crucial role, too
Phase Early escalation Weeks 5-8 Weekly Dose 4 mg Notes Increase by 2 mg every 4 weeks